The $40m D round for AM-Pharma was co-led by venture capital firms Ysios Capital Partners and Kurma Life Science Partners and included peers Forbion Capital Partners (which was spun out of local bank ABN Amro), BB Biotech Ventures and Idinvest Partners as well as Inventages Venture Capital, which invests on behalf of Switzerland-based chocolate maker Nestle, Abbott and Shire.

GE Healthcare and a selection of VC firms have put aside up to $100m in funding for companies with innovative ideas to combat breast cancer.

News provider Globes said Aharon Schwartz, vice-president of Teva Innovative Ventures, would be "responsible for investing in start-ups and reaching licensing agreements with universities as part of the company's effort to expand its pipeline of innovative drugs".

Buyout firm Welsh Carson takes control of the diabetes treatment company as part of the C round.

As part of its $25m in non-dilutive debt, Myriad has a three-year option to acquire Crescendo Bioscience for a predetermined multiple of revenue based on its current growth rate.

The Amgen-backed biotech company, which has signed a lucrative research deal with Pfizer, is now looking to complement it with venture financing.

Baxter Ventures will report into Norbert Riedel, Baxter's chief scientific officer.